Dr. Feinstein Speaks at 2024 World Conference on Lung Cancer
Dr. Trevor Feinstein, spoke to over 1,000 attendees at the 2024 World Conference on Lung Cancer.
Dr. Feinstein, a noted expert on lung cancer, presented data on Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial. The conclusions of the study: In patients with advance EGFR wild-type platinum refractory NSCLC (Non-Small Cell Lung Cancer), plinabulin combined with docetaxel was well-tolerated and statistically significantly improved OS(overall survival)/PFS(progression-free survival)/ORR(overall response rate) with reduced severe neutropenia(low levels of white blood cells). A durable anti-cancer benefit was observed suggesting that plinabulin/docetaxel as a potential practice-changing treatment for advanced/metastatic NSCLC without driver mutations.
See the full abstract here: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00178-4/abstract
